PeerJ (Aug 2016)
Minimum information about tolerogenic antigen-presenting cells (MITAP): a first step towards reproducibility and standardisation of cellular therapies
- Phillip Lord,
- Rachel Spiering,
- Juan C. Aguillon,
- Amy E. Anderson,
- Silke Appel,
- Daniel Benitez-Ribas,
- Anja ten Brinke,
- Femke Broere,
- Nathalie Cools,
- Maria Cristina Cuturi,
- Julie Diboll,
- Edward K. Geissler,
- Nick Giannoukakis,
- Silvia Gregori,
- S. Marieke van Ham,
- Staci Lattimer,
- Lindsay Marshall,
- Rachel A. Harry,
- James A. Hutchinson,
- John D. Isaacs,
- Irma Joosten,
- Cees van Kooten,
- Ascension Lopez Diaz de Cerio,
- Tatjana Nikolic,
- Haluk Barbaros Oral,
- Ljiljana Sofronic-Milosavljevic,
- Thomas Ritter,
- Paloma Riquelme,
- Angus W. Thomson,
- Massimo Trucco,
- Marta Vives-Pi,
- Eva M. Martinez-Caceres,
- Catharien M.U. Hilkens
Affiliations
- Phillip Lord
- School of Computing Science, Newcastle University, Newcastle upon Tyne, United Kingdom
- Rachel Spiering
- Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom
- Juan C. Aguillon
- Instituto de Ciencias Biomédicas (ICBM), Universidad de Chile, Santiago, Chile
- Amy E. Anderson
- Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom
- Silke Appel
- Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway
- Daniel Benitez-Ribas
- Department of Immunology, Hospital Clínic i Provincial and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, Spain
- Anja ten Brinke
- Department of Immunopathology, Sanquin Research, Amsterdam, The Netherlands
- Femke Broere
- Faculty of Veterinary Medicine, Department of Infectious Diseases and Immunology, Utrecht University, Utrecht, The Netherlands
- Nathalie Cools
- Laboratory of Experimental Hematology, Vaccine & Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, Belgium
- Maria Cristina Cuturi
- Center for Research in Transplantation and Immunology, ITUN, Inserm UMRS 1064, Nantes, France
- Julie Diboll
- Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom
- Edward K. Geissler
- Department of Surgery, Section of Experimental Surgery, University Hospital Regensburg, Regensburg, Germany
- Nick Giannoukakis
- Institute of Cellular Therapeutics, Allegheny Health Network, Pittsburgh, PA, United States of America
- Silvia Gregori
- San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), Division of Regenerative Medicine, Stem Cells and Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy
- S. Marieke van Ham
- Department of Immunopathology, Sanquin Research, Amsterdam, The Netherlands
- Staci Lattimer
- School of Computing Science, Newcastle University, Newcastle upon Tyne, United Kingdom
- Lindsay Marshall
- School of Computing Science, Newcastle University, Newcastle upon Tyne, United Kingdom
- Rachel A. Harry
- Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom
- James A. Hutchinson
- Department of Surgery, Section of Experimental Surgery, University Hospital Regensburg, Regensburg, Germany
- John D. Isaacs
- Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom
- Irma Joosten
- Department of Laboratory Medicine, Radboud University medical center, Nijmegen, The Netherlands
- Cees van Kooten
- Department of Nephrology, Leiden University Medical Centre, Leiden, The Netherlands
- Ascension Lopez Diaz de Cerio
- Area of Cell Therapy, University Clinic of Navarra, Pamplona, Spain
- Tatjana Nikolic
- Department of Immunohematology and Blood Transfusion, Leiden University Medical Centre, Leiden, The Netherlands
- Haluk Barbaros Oral
- Department of Immunology, Faculty of Medicine, Uludag University, Bursa, Turkey
- Ljiljana Sofronic-Milosavljevic
- Institute for the Application of Nuclear Energy INEP, University of Belgrade, Belgrade, Serbia
- Thomas Ritter
- Regenerative Medicine Institute (REMEDI), School of Medicine, College of Medicine, Nursing and Health Sciences, National University of Ireland, Galway, Ireland
- Paloma Riquelme
- Department of Surgery, Section of Experimental Surgery, University Hospital Regensburg, Regensburg, Germany
- Angus W. Thomson
- Thomas E. Starzl Transplantation Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States of America
- Massimo Trucco
- Institute of Cellular Therapeutics, Allegheny Health Network, Pittsburgh, PA, United States of America
- Marta Vives-Pi
- Immunology Division, Germans Trias i Pujol University Hospital and Health Sciences Research Institute, Badalona, Spain
- Eva M. Martinez-Caceres
- Immunology Division, Germans Trias i Pujol University Hospital and Health Sciences Research Institute, Badalona, Spain
- Catharien M.U. Hilkens
- Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom
- DOI
- https://doi.org/10.7717/peerj.2300
- Journal volume & issue
-
Vol. 4
p. e2300
Abstract
Cellular therapies with tolerogenic antigen-presenting cells (tolAPC) show great promise for the treatment of autoimmune diseases and for the prevention of destructive immune responses after transplantation. The methodologies for generating tolAPC vary greatly between different laboratories, making it difficult to compare data from different studies; thus constituting a major hurdle for the development of standardised tolAPC therapeutic products. Here we describe an initiative by members of the tolAPC field to generate a minimum information model for tolAPC (MITAP), providing a reporting framework that will make differences and similarities between tolAPC products transparent. In this way, MITAP constitutes a first but important step towards the production of standardised and reproducible tolAPC for clinical application.
Keywords
- Cell therapy
- Minimum information model
- Antigen-presenting cells
- Autoimmune disease
- Transplantation
- Tolerogenic dendritic cells
